论文部分内容阅读
研究ATP结合盒(ABC)转运体ABCG2、ABCB5在多发性骨髓瘤(MM)RPMI-8226和NCI-H929细胞的表达及意义。方法:用实时定量反转录酶-聚合酶链锁反应(qRT-PCR)及蛋白印迹(Western blot)法检测MM细胞中ABCG2、AB-CB5的表达,并观察两株细胞在增殖、克隆、耐药及致瘤性等方面的差异。结果:qRT-PCR和Western blot显示AB-CG2、ABCB5均表达于RPMI-8226和NCI-H929细胞,且前者的表达水平较后者明显增高(P<0.05)。与NCI-H929细胞相比,增殖、克隆、耐药实验,RPMI-8226细胞增殖速度快、克隆形成能力强、对长春新碱的耐受性高(P<0.05)。成瘤实验显示第10周时RPMI-8226组鼠出现了肿瘤而NCI-H929组鼠始终未出现肿瘤。ABCG2、ABCB5高表达于RPMI-8226细胞,可能是其耐药性较NCI-H929细胞增高的机制之一。这将为MM细胞化疗药物的筛选和靶向耐药分子ABCG2、AB-CB5治疗MM提供实验依据。
To study the expression and significance of ATP-binding cassette (ABC) transporters ABCG2 and ABCB5 in multiple myeloma (MM) RPMI-8226 and NCI-H929 cells. Methods: The expression of ABCG2 and AB-CB5 in MM cells was detected by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and Western blotting. The proliferation, Drug resistance and tumorigenicity and other differences. Results: qRT-PCR and Western blot showed that AB-CG2 and ABCB5 were both expressed in RPMI-8226 and NCI-H929 cells, and the expression of AB-CG2 and ABCB5 was significantly higher than the latter (P <0.05). Compared with NCI-H929 cells, RPMI-8226 cells proliferated rapidly, cloned and resistant, and their ability of clonogenicity was high and their resistance to vincristine was high (P <0.05). Tumorigenicity experiments showed that in the tenth week, the tumor appeared in the RPMI-8226 group mice and the NCI-H929 group mice did not appear the tumor all the time. The high expression of ABCG2 and ABCB5 in RPMI-8226 cells may be one of the mechanisms of their increased drug resistance compared with NCI-H929 cells. This will provide experimental evidence for the screening of MM cell chemotherapeutic drugs and the targeting of drug resistant molecules ABCG2 and AB-CB5.